NCT03581942View on ClinicalTrials.gov

Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 23, 2018

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Interventions
DRUG

Ibrutinib

(MTD) Dose Escalation level 2: Ibrutinib 840 mg daily

DRUG

Copanlisib

(MTD) Copanlisib 60 mg weekly (3w on/1w off)

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack

07920

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER